Find Trametinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 871700-17-3, Gsk1120212, Mekinist, Gsk-1120212, Jtp 74057, Jtp-74057
Molecular Formula
C26H23FIN5O4
Molecular Weight
615.4  g/mol
InChI Key
LIRYPHYGHXZJBZ-UHFFFAOYSA-N
FDA UNII
33E86K87QN

Trametinib
Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.
Trametinib is a Kinase Inhibitor. The mechanism of action of trametinib is as a Protein Kinase Inhibitor.
1 2D Structure

Trametinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
2.1.2 InChI
InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
2.1.3 InChI Key
LIRYPHYGHXZJBZ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
2.2 Other Identifiers
2.2.1 UNII
33E86K87QN
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Gsk 1120212

2. Gsk-1120212

3. Gsk1120212

4. Jtp 74057

5. Jtp-74057

6. Jtp74057

2.3.2 Depositor-Supplied Synonyms

1. 871700-17-3

2. Gsk1120212

3. Mekinist

4. Gsk-1120212

5. Jtp 74057

6. Jtp-74057

7. Gsk 1120212

8. Trametinib (gsk1120212)

9. N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]acetamide

10. Gsk212

11. Tmt212

12. Trametinib [usan]

13. Chebi:75998

14. Tmt-212

15. 33e86k87qn

16. Trametinib (usan)

17. N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl}phenyl)acetamide

18. N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide

19. Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- Dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)-

20. N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl)phenyl)acetamide

21. Unii-33e86k87qn

22. Trametinib [usan:inn]

23. Trametinibum

24. Jtp74057

25. N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- Tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)acetamide

26. N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl)phenyl)acetamide

27. N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- Tetrahydropyrido(4,3-d)pyrimidin-1(2h)-yl}phenyl)acetamide

28. Qom

29. Trametinib [mi]

30. Trametinib (gsk1120212jtp 74057)

31. Trametinib [inn]

32. Trametinib [vandf]

33. Trametinib [who-dd]

34. Schembl170938

35. Gtpl6495

36. Gsk1120212 (trametinib)

37. Chembl2103875

38. Ex-a022

39. Bcpp000218

40. Dtxsid901007381

41. Hms3295i05

42. Hms3656j11

43. Bcp02307

44. Bdbm50531540

45. Mfcd17215075

46. Nsc758246

47. Nsc800956

48. S2673

49. Zinc43100709

50. Akos015850628

51. Am90271

52. Ccg-264976

53. Cs-0060

54. Db08911

55. Ex-5957

56. Nsc-758246

57. Nsc-800956

58. Sb16553

59. Ncgc00263180-01

60. Ncgc00263180-07

61. Ncgc00263180-14

62. Ac-25891

63. As-19382

64. Hy-10999

65. N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide

66. Ft-0688438

67. Sw218089-2

68. A25168

69. D10175

70. Gsk1120212 - Jtp-74057

71. Gsk1120212,jtp-74057, Gsk212

72. Sr-01000941589

73. A1-01871

74. J-523325

75. Q7833138

76. Sr-01000941589-1

77. Brd-k12343256-001-01-4

78. Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl]-

79. N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl)phenyl)acetamide

80. N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe Nyl]acetamide

81. N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide

82. N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2h)-yl]phenyl}ethanimidic Acid

83. N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 615.4 g/mol
Molecular Formula C26H23FIN5O4
XLogP33.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count5
Exact Mass615.07788 g/mol
Monoisotopic Mass615.07788 g/mol
Topological Polar Surface Area102 Ų
Heavy Atom Count37
Formal Charge0
Complexity1090
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameMekinist
PubMed HealthTrametinib (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelTrametinib dimethyl sulfoxide is a kinase inhibitor. The chemical name is acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4- iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl- 2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-, compound with 1,1-sul...
Active IngredientTrametinib dimethyl sulfoxide
Dosage FormTablet
RouteOral
Strengtheq 1mg non-solvated parent; eq 0.5mg non-solvated parent; eq 2mg non-solvated parent
Market StatusPrescription
CompanyGlaxosmithkline

2 of 2  
Drug NameMekinist
PubMed HealthTrametinib (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelTrametinib dimethyl sulfoxide is a kinase inhibitor. The chemical name is acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4- iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl- 2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-, compound with 1,1-sul...
Active IngredientTrametinib dimethyl sulfoxide
Dosage FormTablet
RouteOral
Strengtheq 1mg non-solvated parent; eq 0.5mg non-solvated parent; eq 2mg non-solvated parent
Market StatusPrescription
CompanyGlaxosmithkline

4.2 Drug Indication

Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test [FDA]. In May 2018, it was approved for use with [DB08912] for the treatment of treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.


FDA Label


* Melanoma:

Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).

Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5. 1).

* Adjuvant treatment of melanoma:

Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

* Non-small cell lung cancer (NSCLC):

Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Trametinib is an anticancer agent which causes apoptosis (or programmed cell death) and inhibits cell proliferation, which are both important in the treatment of malignancies.


5.2 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
TRAMETINIB
5.3.2 FDA UNII
33E86K87QN
5.3.3 Pharmacological Classes
Protein Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
5.4 ATC Code

L01EE01


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EE - Mitogen-activated protein kinase (mek) inhibitors

L01EE01 - Trametinib


5.5 Absorption, Distribution and Excretion

Absorption

Trametinib is readily absorbed. When an oral administration of trametinib was given to patients with BRAF V600 mutation-positive melanoma, peak plasma concentration occurred 1.5 hours post-dose (Tmax). A single 2 mg oral dose has a bioavailability of 72%. When a dose of 2mg/day is given, the peak plasma concentration (Cmax) is 22.2 ng/mL.


Route of Elimination

80% of the dose is excreted in the feces. <20% of the dose is excreted in the urine with <0.1% of the excreted dose in the form of the parent compound.


Volume of Distribution

Apparent volume of distribution (Vd/F) = 214 L


Clearance

Apparent clearance = 4.9 L/h


5.6 Metabolism/Metabolites

Trametinib is metabolized predominantly via deacetylation alone or with mono-oxygenation or in combination with glucuronidation biotransformation pathways in vitro. Deacetylation is likely mediated by hydrolytic enzymes, such as carboxyl-esterases or amidases. The cytochrome P450 enzyme system is not involved with the metabolism of trametinib. The predominant circulating component in the plasma is the parent drug.


5.7 Biological Half-Life

Elimination half-life = 3.9-4.8 days.


5.8 Mechanism of Action

Trametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 _(MEK1)_ and _MEK2_ activation and of_ MEK1_ and _MEK2_ kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. Trametinib helps with melanoma with the BRAF V600E or V600K as the mutation results in the constitutive activation of the BRAF pathway which includes MEK1 and MEK2.


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Flag Poland
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39561

Submission : 2024-06-19

Status : Active

Type : II

Polpharma CB

02

Bioprocess International Europe
Not Confirmed

02

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40493

Submission : 2024-09-29

Status : Active

Type : II

blank

03

Bioprocess International Europe
Not Confirmed

03

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-10-18

Pay. Date : 2022-09-12

DMF Number : 37504

Submission : 2022-09-13

Status : Active

Type : II

blank

04

Biocon Ltd

India

USDMF

arrow
Bioprocess International Europe
Not Confirmed

04

Biocon Ltd

India
arrow
Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43478

Submission : 2026-03-24

Status : Active

Type : II

blank

05

Bioprocess International Europe
Not Confirmed

05

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-03-31

Pay. Date : 2022-01-06

DMF Number : 35525

Submission : 2020-12-31

Status : Active

Type : II

blank

06

Bioprocess International Europe
Not Confirmed

06

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2026-04-09

Pay. Date : 2026-02-27

DMF Number : 31589

Submission : 2017-03-31

Status : Active

Type : II

blank

07

Bioprocess International Europe
Not Confirmed

07

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43552

Submission : 2026-03-21

Status : Active

Type : II

blank

08

Bioprocess International Europe
Not Confirmed

08

Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43513

Submission : 2026-01-30

Status : Active

Type : II

blank

09

Valary Lab Private Limited

Country

USDMF

arrow
Bioprocess International Europe
Not Confirmed

09

Valary Lab Private Limited

Country
arrow
Bioprocess International Europe
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40250

Submission : 2024-08-23

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB

NDC Package Code : 59651-710

Start Marketing Date : 2024-01-11

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank

02

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB

NDC Package Code : 73377-309

Start Marketing Date : 2025-02-06

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

03

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB

NDC Package Code : 52482-014

Start Marketing Date : 2014-09-02

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

NDC Package Code : 54893-0106

Start Marketing Date : 2020-12-30

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB

NDC Package Code : 54893-0062

Start Marketing Date : 2017-03-31

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

NDC Package Code : 44139-0102

Start Marketing Date : 2016-03-17

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

VALARY LAB PRIVATE LIMITED

Country
PCC
Not Confirmed
arrow

VALARY LAB PRIVATE LIMITED

Country
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

NDC Package Code : 81955-0020

Start Marketing Date : 2013-05-29

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Polpharma

Poland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

Flag Poland
Digital Content Digital Content

Trametinib Dimethyl Sulfoxide

About the Company : Polpharma API, a division of a leading Polish pharmaceutical group, has over 75 years of expertise in process development and cGMP manufacturing. Based at an FDA-approved site in C...

Polpharma API, a division of a leading Polish pharmaceutical group, has over 75 years of expertise in process development and cGMP manufacturing. Based at an FDA-approved site in Central Europe, it offers comprehensive API services from development to scale-up. Specializing in small molecule clinical candidates, Polpharma delivers customized, high-quality solutions with strong regulatory knowledge and advanced infrastructure. Globally recognized for complex chemistry, it is committed to precision, partnership, and progress. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Polpharma CB

02

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Trametinib

About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

03

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

04

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib

About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
blank

05

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib

About the Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with...

Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in 2017 by a team with vast experience across the pharmaceutical value chain, the company is on a mission to become the most preferred partner for pharmaceuticals. At Aurore, we aim to push the boundaries to manufacture and deliver high quality products that can be relied upon by both customers and regulators. Our thrust on rapidly adding capabilities have led us to acquire, integrate and expand our reach across the geographies.
blank

06

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib

About the Company : Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, o...

Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, optimized management and robust service system for our customers. Daishang Chem is specialized in the researching, manufacturing, sales and marketing of API & Its Intermediates as well as other Fine Chemicals, taking great advantages of professional and proficient staff, based on three chemical manufacturing sites and one GMP manufacturing workshops in Liaoning, Henan and Zhejiang provinces, and one R&D laboratory in Zhangjiang Hi-tech Park.
blank

07

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib DMSO

About the Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients an...

Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients and intermediates. We are specialized in applying organic catalysts into the process development to lower cost, and to provide cost-effective product and service to customers. With our strong R&D capability and our proprietary organic catalysts, we provide low cost and high quality active pharmaceutical ingredients and intermediates to pharmaceutical companies. We also provide world standard process development, custom synthesis and manufacturing service.
blank

08

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib

About the Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients an...

Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients and intermediates. We are specialized in applying organic catalysts into the process development to lower cost, and to provide cost-effective product and service to customers. With our strong R&D capability and our proprietary organic catalysts, we provide low cost and high quality active pharmaceutical ingredients and intermediates to pharmaceutical companies. We also provide world standard process development, custom synthesis and manufacturing service.
blank

09

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib

About the Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get...

Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get the domestic registration of their finished dosage for their international expansion. Our USFDA approved products Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Dasatinib Monohydrate, Oxaliplatin and Temozolomide have been recognized by our customers globally. In addition, our Amisulpride API acquired CEP, UK GMP & USDMF.
blank

10

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Trametinib

About the Company : Shenzhen HwaGen Pharmaceutical Co., Ltd. (HwaGen Pharma) was founded in December of 2015 under the leadership of a “National 1000 Talents Program” expert. By leveraging its cor...

Shenzhen HwaGen Pharmaceutical Co., Ltd. (HwaGen Pharma) was founded in December of 2015 under the leadership of a “National 1000 Talents Program” expert. By leveraging its core competency in chiral synthesis, enzymatic catalysis and continuous flow micro reactor, HwaGen Pharmaceutical is dedicated to development and manufacturing of specialty and niche intermediates and APIs covering various therapeutic areas including oncology, antiviral and respiratory, delivering high value-added and affordable products for global pharmaceutical industry. Equipments for Analysis & Test include Tabletop NMR, LC-MS, GC, HPLC etc.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Hikma Pharmaceuticals

United Kingdom
PCC
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

Brand Name : TRAMETINIB DIMETHYL SULFOXIDE

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 0.5MG

Packaging :

Approval Date : 2024-08-06

Application Number : 219002

Regulatory Info : DISCN

Registration Country : USA

blank

02

Hikma Pharmaceuticals

United Kingdom
PCC
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

Brand Name : TRAMETINIB DIMETHYL SULFOXIDE

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 2MG

Packaging :

Approval Date : 2024-08-06

Application Number : 219002

Regulatory Info : DISCN

Registration Country : USA

blank

03

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

Brand Name : MEKINIST

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 0.5MG

Packaging :

Approval Date : 2013-05-29

Application Number : 204114

Regulatory Info : RX

Registration Country : USA

blank

04

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

Brand Name : MEKINIST

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Packaging :

Approval Date : 2013-05-29

Application Number : 204114

Regulatory Info : DISCN

Registration Country : USA

blank

05

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

Brand Name : MEKINIST

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 2MG

Packaging :

Approval Date : 2013-05-29

Application Number : 204114

Regulatory Info : RX

Registration Country : USA

blank

06

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB DIMETHYL SULFOXIDE

Brand Name : MEKINIST

Dosage Form : SOLUTION;ORAL

Dosage Strength : EQ 0.05MG BASE/ML

Packaging :

Approval Date : 2023-03-16

Application Number : 217513

Regulatory Info : RX

Registration Country : USA

blank

07

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB

Brand Name : MEKINIST

Dosage Form : TABLET;ORAL

Dosage Strength : 2MG

Packaging :

Approval Date :

Application Number : 217513

Regulatory Info :

Registration Country : USA

blank

08

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

TRAMETINIB

Brand Name : MEKINIST

Dosage Form : SOLUTION;ORAL

Dosage Strength : 4.7MG

Packaging :

Approval Date :

Application Number : 217513

Regulatory Info :

Registration Country : USA

blank

09

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Tramway

Brand Name : Mekinist

Dosage Form : Film Coated Tablet

Dosage Strength : 0.5mg

Packaging :

Approval Date : 22/02/2016

Application Number : 65883

Regulatory Info : Allowed

Registration Country : Switzerland

blank

10

PCC
Not Confirmed
arrow
arrow
PCC
Not Confirmed

Tramway

Brand Name : Mekinist

Dosage Form : Film Coated Tablet

Dosage Strength : 2mg

Packaging :

Approval Date : 22/02/2016

Application Number : 65883

Regulatory Info : Allowed

Registration Country : Switzerland

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - EQ 0.5MG

USFDA APPLICATION NUMBER - 204114

read-more

DOSAGE - TABLET;ORAL - EQ 1MG **Federal Regis...DOSAGE - TABLET;ORAL - EQ 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 204114

read-more

DOSAGE - TABLET;ORAL - EQ 2MG

USFDA APPLICATION NUMBER - 204114

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Controlled & Modified Release

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Solubilizers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Taste Masking

read-more
read-more

Lubricants & Glidants

read-more
read-more

Topical

read-more
read-more

Co-Processed Excipients

read-more
read-more

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Emulsifying Agents

read-more
read-more

Empty Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 871700-17-3 / Trametinib API manufacturers, exporters & distributors?

Trametinib manufacturers, exporters & distributors 1

86

PharmaCompass offers a list of Trametinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Trametinib manufacturer or Trametinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Trametinib manufacturer or Trametinib supplier.

API | Excipient name

Trametinib

Synonyms

871700-17-3, Gsk1120212, Mekinist, Gsk-1120212, Jtp 74057, Jtp-74057

Cas Number

871700-17-3

Unique Ingredient Identifier (UNII)

33E86K87QN

About Trametinib

Trametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.

Trametinib Manufacturers

A Trametinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trametinib, including repackagers and relabelers. The FDA regulates Trametinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trametinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Trametinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Trametinib Suppliers

A Trametinib supplier is an individual or a company that provides Trametinib active pharmaceutical ingredient (API) or Trametinib finished formulations upon request. The Trametinib suppliers may include Trametinib API manufacturers, exporters, distributors and traders.

click here to find a list of Trametinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Trametinib USDMF

A Trametinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Trametinib active pharmaceutical ingredient (API) in detail. Different forms of Trametinib DMFs exist exist since differing nations have different regulations, such as Trametinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Trametinib DMF submitted to regulatory agencies in the US is known as a USDMF. Trametinib USDMF includes data on Trametinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Trametinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Trametinib suppliers with USDMF on PharmaCompass.

Trametinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Trametinib Drug Master File in Korea (Trametinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Trametinib. The MFDS reviews the Trametinib KDMF as part of the drug registration process and uses the information provided in the Trametinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Trametinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Trametinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Trametinib suppliers with KDMF on PharmaCompass.

Trametinib WC

A Trametinib written confirmation (Trametinib WC) is an official document issued by a regulatory agency to a Trametinib manufacturer, verifying that the manufacturing facility of a Trametinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Trametinib APIs or Trametinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Trametinib WC (written confirmation) as part of the regulatory process.

click here to find a list of Trametinib suppliers with Written Confirmation (WC) on PharmaCompass.

Trametinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Trametinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Trametinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Trametinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Trametinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Trametinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Trametinib suppliers with NDC on PharmaCompass.

Trametinib GMP

Trametinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Trametinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Trametinib GMP manufacturer or Trametinib GMP API supplier for your needs.

Trametinib CoA

A Trametinib CoA (Certificate of Analysis) is a formal document that attests to Trametinib's compliance with Trametinib specifications and serves as a tool for batch-level quality control.

Trametinib CoA mostly includes findings from lab analyses of a specific batch. For each Trametinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Trametinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Trametinib EP), Trametinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trametinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty